 |
|---|
Scott Johnson |
December 7, 2006
Earlier this month, I was recognized by Scientific American magazine for policy leadership in advancing new ways to fund medical research. When I started MRF four years ago, I never dreamt it would achieve this level of recognition. I am humbled by this honor and by the accomplishments of the others -- Harvard University economist Michael Kremer, philanthropist Warren Buffet, our friend Kathy Giusti at the Multiple Myeloma Foundation, pioneering geneticist Christiane Nüsselein-Volhard, and former vice president Al Gore -- with whom I shared this recognition.
But this recognition doesn’t really belong to me. Rather it belongs to our extraordinary scientists who through their insights, dedication and hard work have made such dramatic progress toward our goal of identifying drug targets that will lead to treatments for MS. It belongs to our Scientific Advisory Board and Board of Directors who help to keep us focused on the business of managing outcome-directed research. It belongs to our supporters who have not only provided substantial financial support but who also continue to connect us to others who may have an interest in our work. It belongs to our friends in the media and sister non-profit organizations who understand the importance of our work and its potential to speed all medical research. And it belongs to our staff and volunteers who keep this enterprise moving forward at an unimaginable pace.
My gratitude goes to them for this recognition. To each of them I say thank you. I look forward to continuing to share this journey with all of you.
Sincerely,
Scott Johnson
President and Founder
